STK11 mutation + KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation + KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3	camrelizumab + rivoceranib Sensitive: C3 – Early Trials camrelizumab + rivoceranib Sensitive : C3
STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	STK11 mutation + KEAP1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
STK11 mutation + KEAP1 mutation	Lung Cancer	STK11 mutation + KEAP1 mutation	Lung Cancer	STAR-001 Sensitive: D – Preclinical STAR-001 Sensitive : D	STAR-001 Sensitive: D – Preclinical STAR-001 Sensitive : D

STK11 mutation + KEAP1 mutation

Associations